Prosecution Insights
Last updated: November 12, 2026
Application No. 18/787,677

LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM

Non-Final OA §102§112
Filed
Jul 29, 2024
Priority
Apr 14, 2017 — provisional 62/485,890 +4 more
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zevra Therapeutics Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
66%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1452 granted / 1798 resolved
+20.8% vs TC avg
Minimal -14% lift
Without
With
+-14.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
54 currently pending
Career history
1840
Total Applications
across all art units

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are pending in the application. Claim Rejections - 35 USC § 112 3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-9 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for treating pain, does not reasonably provide enablement for treating Alzheimer’s disease, Pseudobulbar effect (PBA), Post traumatic stress disorder (PTSD) and opioid dependency. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The following eight different factors (see Ex parte Foreman, 230 USPQ at 547; Wands, In re, 858.F. 2d 731, 8 USPQ 2d 1400, Fed. Cir. 1988) must be considered in order for the specification to be enabling for what is being claimed: Quantity of experimentation necessary, the amount of direction or guidance provided, presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability and the breadth of claims. In the instant case, the specification is not enabling based on atleast four of the above mentioned eight different factors such as quantity of experimentation necessary, the amount of direction or guidance provided, presence of working examples, state of the prior art, unpredictability and the breadth of claims. The utility of NMDA receptor antagonists for treating pain is well established. However, there is no teaching either in the specification or prior art references provided showing well established utility of NMDA receptor antagonists for treating Alzheimer’s disease, Pseudobulbar effect (PBA), Post traumatic stress disorder (PTSD) and opioid dependency. There are no working examples present showing efficacy of instant compounds in animal models of Alzheimer’s disease, Pseudobulbar effect (PBA), Post traumatic stress disorder (PTSD) and opioid dependency. In absence of such teachings, guidance, prior art and working examples, it would require undue experimentation to demonstrate efficacy of instant compounds in animal models of Alzheimer’s disease, Pseudobulbar effect (PBA), Post traumatic stress disorder (PTSD) and opioid dependency and hence their utility for treating these disease conditions. 6. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claims 1 and 11, the values of variables A, X and Z is defined as O or S. However, compounds do not exist in the art where all variables A, X and Z represent either O or S simultaneously. In independent claim 1, specific diseases mediated by NMDA receptor antagonist are not defined. Claim 19 depends upon claim 25 which is not present in the application. Claim 20 depends upon claim 33 which is not present in the application. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 4-8 are rejected under 35 U.S.C. 102(a) (1) as being anticipated by Cantrell (U.S. Patent 8,829,020, cited on applicant’s form 1449). Cantrell discloses compounds and their salts for treating cancer either alone or in combination with other agents (see column 5, lines 26-45). The compound 14 (see column 81) disclosed by Cantrell anticipates the instant claims when variables L2, Y2 and W are absent, variable M represents CR3R4 (R3 and R4 are H) and Gm2 represents H in the instant compounds. It is of note that NMDA receptor will be inherently inhibited following administration of this compound for treating cancer. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jul 29, 2024
Application Filed
Aug 13, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788011
5-Fluoro-4-Imino-3-Methyl-1-Tosyl-3,4-Dihydropyrimidin-2(1H)-One for Controlling Plant Diseases
3y 3m to grant Granted Nov 10, 2026
Patent 12780820
3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
3y 9m to grant Granted Nov 03, 2026
Patent 12780843
A SYNTHESIS OF COPPER (I) 5-NITROTETRAZOLATE
3y 1m to grant Granted Nov 03, 2026
Patent 12778958
Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto
3y 1m to grant Granted Nov 03, 2026
Patent 12787633
TETRADENTATE PLATINUM AND PALLADIUM COMPLEXES BASED ON BISCARBAZOLE AND ANALOGUES
2y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
66%
With Interview (-14.4%)
Low
PTA Risk
Based on 1798 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month